关键信息
-
基因名
PKC iota
- 应用
-
别名
PKC-I; PRKCI; PRKC-I; NPKC-Iota; Atypical protein kinase C-lambda/iota
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P41743
-
表达区间
Ile375~Val596
-
分子量
32kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
PKC iota (Protein Kinase C iota) is a member of the protein kinase C (PKC) family, which plays a crucial role in various cellular processes, including cell proliferation, differentiation, and survival. Unlike other PKC isoforms, PKC iota is particularly involved in signaling pathways related to cancer progression and metastasis. Research has shown that PKC iota is often overexpressed in several types of cancers, including breast, prostate, and colorectal cancers, thus suggesting its potential as a therapeutic target. The understanding of PKC iota's structure and function is essential for developing targeted therapies. The recombinant production of PKC iota allows researchers to investigate its biochemical properties, identify substrate interactions, and explore its role in oncogenic signaling pathways. By studying the recombinant protein in vitro, scientists aim to dissect the mechanisms through which PKC iota contributes to tumorigenesis and to evaluate its potential as a biomarker for cancer diagnosis and prognosis. Ultimately, this research may pave the way for novel cancer treatments that effectively inhibit PKC iota activity, improving outcomes for patients with malignancies characterized by its dysregulation.
